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The increased need for macromolecular therapeutics, such as peptides, proteins and 
nucleotides, to reach intracellular targets necessitates more effective delivery vectors and a 
higher level of understanding of their mechanism of action. Cell penetrating peptides (CPPs) 
can transport a range of macromolecules into cells, either through direct plasma membrane 
	 2	
translocation or endocytosis. All known endocytic pathways involve cell-cortex remodelling, 
a process shown to be regulated by reorganisation of the actin cytoskeleton. Here using flow 
cytometry, confocal microscopy and a variety of actin inhibitors we identify how actin 
disorganisation in different cell types differentially influences the cellular entry of three probes: 
the CPP octaarginine – Alexa488 conjugate (R8-Alexa488), octaarginine conjugated Enhanced 
Green Fluorescent Protein (EGFP-R8), and the fluid phase probe dextran.  Disrupting actin 
organisation in A431 skin epithelial cells dramatically increases the uptake of EGFP-R8 and 
dextran, and contrasts strongly to inhibitory effects observed with transferrin and R8 attached 
to the fluorophore Alexa488. This demonstrates that uptake of the same CPP can occur via 
different endocytic processes depending on the conjugated fluorescent entity. Overall this study 
highlights how cargo influences cell uptake of this peptide and that the actin cytoskeleton may 
act as a gateway or barrier to endocytosis of drug delivery vectors.  
 
1. Introduction 
Cell penetrating peptides (CPPs) are a group of short sequences typically containing 5-30 
amino acids that have been extensively investigated as carriers for intracellular delivery of 
various cargos including genetic material, peptides, proteins and nanoparticles
1-4
 Numerous 
efforts have been made to unveil the mechanisms of CPP translocation to the cytoplasm and 
cytosol of cells, and it is now well accepted that two modes of cell entry exist: direct membrane 
translocation, which may be energy and temperature independent, and uptake via one or more 
energy dependent endocytic pathways 
5,6
. The propensity for uptake via these mechanisms is 
dependent on the peptide sequence, choice of cargo, in vitro model and can be influenced by 
experimental factors, including incubation temperature and the presence or absence of serum 
in media 
7
. In a number of CPP studies an intact actin cytoskeleton has been proposed to be 
required for cell internalisation and CPPs inside and outside of cells can modify the actin 
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cytoskeleton to influence cellular processes including CPP entry 
8-11
. 
One endocytic pathway that is absolutely reliant on actin is macropinocytosis. When activated 
this process has the capacity to form large plasma membrane derived intracellular vesicles 
termed macropinosomes 
12-15
. Classically macropincytosis is induced in response to growth 
factor activation such as epidermal growth factor (EGF) binding to the EGF receptor, initially 
leading to extensive actin-dependent ruffling on the plasma membrane. This induces a “gulping 
effect” manifest as an increased uptake of extracellular fluid 
13,14,16
. Much of the information 
known regarding growth factor induced and actin dependent macropinocytosis comes from 
studies on high EGFR expressing A431 skin epithelia cells and their response to EGF 
13,17,18
. 
Of interest are observations that some CPPs under defined experimental conditions may induce 
plasma membrane effects similar to that seen upon growth factor activation 
19-21
 and in line 
with this that they promote the concomitant uptake of dextran, a well characterised marker of 
fluid phase endocytosis 
22-24
.  Dextran itself, in addition to being widely used as a fluid phase 
endocytic probe has been extensively investigated as a drug delivery vector	25.	
Tools used routinely to examine the roles of the actin cytoskeleton in various cellular processes, 
including endocytosis and CPP entry are pharmacological/chemical inhibitors. The most 
notable such agent is the fungal metabolite cytochalasin D (Cyt D)  which disrupts actin 
polymerisation and is a well characterised inhibitor of various endocytic mechanisms	
26-28
. 
Other natural compounds and synthetic products such as Latrunculin B (Lat B) and 
Jasplakinolide (JAS) have been identified or developed to target the actin directly or indirectly 
and to disrupt its organisation and function
29
. Very few studies have investigated the effects of 
these other actin disrupters on CPP uptake though it is generally recognised that actin 
disruption universally inhibits CPP entry.  
Here we show that the effects of actin disruption on uptake of CPPs and dextran is cell type 
dependant and in A431 skin epithelia, in complete contrast to HeLa cells, leads to a dramatic 
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increase in uptake of EGFP-R8 and dextran but inhibits the uptake of R8-Alexa488. Together 
the data indicate that actin organisation has very different influences on uptake of these 
octaarginine and fluid phase conjugates and that actin could be targeted to enhance cellular 
uptake of drug delivery vectors.  
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2. Materials and methods 
2.1 Cell culture  
HeLa (cervical carcinoma, epithelial) cells (ATCC Code CCL-2) or A431 (skin epidermal) 
cells (ATCC Code CRL-1555) were maintained in growth Dulbecco’s Modified Eagle’s 
medium (D-MEM) supplemented with foetal bovine serum (10%, final volume) and 
penicillin/streptomycin (100 units/ml and 100 µg/ml respectively), herein referred to as 
complete medium in a humidified 5% CO2/37˚C incubator as a subconfluent monolayer. Cells 
were obtained from the ATCC and were routinely tested for mycoplasma.  
2.2 Peptide Labelling 
Peptide octaarginine (R8), extended with GC at its C-terminal (RRRRRRRR-GC), was 
synthesized by American Peptide Company (California, USA) and labelled with Alexa Fluor
®
 
488 C5 maleimide salt (Invitrogen, Paisley, UK) as previously described 
30
.  Labelling and 
conjugate mass (2126.5 Da) was confirmed by matrix-assisted laser-desorption ionization–
time-of-flight spectrometry and quantified by UV spectrometry. All labelled peptides were 
resuspended to a stock concentration of 1 mM in autoclaved distilled water, aliquoted and 
frozen at -80˚C until needed.	
2.3 Expression and purification of recombinant proteins 
Plasmids encoding histidine tagged - EGFP-octaarginine, or - EGFP referred to here as EGFP-
R8 or EGFP, were a kind gift from Professor Shiroh Futaki, University of Kyoto, Japan. To 
produce the plasmid the DNA fragment encoding EGFP was amplified from pEGFP-N1 
(Clontech) using primers possessing the sequences for NdeI followed by His6, and R8 and stop 
codon followed by EcoRI. The fragment was cleaved by NdeI and EcoRI and cloned into a 
pET3b (Novagen) derivative without N-terminal T7.Tag sequence to construct E. Coli 
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expression vector pEV3b 
31
 that has NdeI and EcoRI sites within the multi cloning site. Proteins 
were produced in E.coli BL21 (DE3) cells and assessed for purity and molecular weight as 
described in Supplementary Information and shown in Supplementary Fig. 1.  
 2.4 Live cell imaging of endocytic probes and R8 conjugates.  
HeLa or A431 cells were seeded on 35 mm MatTek dishes (Ashland, US) at respective 
densities of 5 × 10
5
 cells/dish and 1.0 × 10
6
 cells/dish and maintained in 2.5 mL D-MEM 
containing 10 %, 100 IU/mL penicillin and 100 µg/mL streptomycin. Cells were then allowed 
to adhere for 24 hr at 37°C/5% CO2 
to reach a confluence of ~80 %. On the day of 
experimentation, they were washed with PBS and then incubated with 100 µl serum-free D-
MEM (thus reducing well described serum binding effects
32
) containing either 2 µM CPP 
conjugate (R8-Alexa488 or EGFP-R8), 5 µg/ml transferrin-Alexa 647 (TF-647) or 0.1 mg/ml 
dextran (10 kDa)-Alexa 647 (Dex-647). The cells were then incubated for 1 hr (or 30 min for 
TF-647) at 37°C/5% CO2 before washing 3x with PBS (TF-647 or Dex-647) or PBS 0.5 mg/mL 
heparin (R8-conjugates). They were then washed once with PBS, prior to the addition of 2 mL 
of imaging medium (phenol red free RPMI, 20 mM HEPES pH 7.4) and analysis by live cell 
confocal microscopy. 
2.5 Actin inhibition and confocal microscopy of endocytic probes and R8 conjugates 
Cells were seeded on MatTek dishes as previously described and were washed with PBS before 
preincubation at 37˚C with diluent control (DMSO) or actin inhibitors: 10 µM Cyt D for 15 
min; 0.1-1 µM Lat B for 30 min; 0.2-4 µM JAS for 45 min; 50-100 µM Y27632 for 4 hr in 
serum-free D-MEM at 37°C/5% CO2. Endocytic probes (TF-647, Dex-647) or R8-conjugates 
were then incubated with the cells in the absence (control) or presence of the inhibitors and 
further incubated at 37°C/5% CO2 for times specified in figure legends prior to analysis by 
confocal microscopy. For pulse chase experiments, A431 cells were incubated with 0.1 mg/ml 
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Dex-647 for 2 hr (pulse) followed by washing and a further 4 hr (chase) in fresh complete 
growth medium. EGFP-R8 (2 µM) was then added for 1 hr in the absence or presence of 10 
µM Cyt D. EGFP-R8 and Dex-647 subcellular distribution was then analysed in live cells using 
confocal microscopy. For low temperature experiments, cells were preincubated with Cyt D as 
above and then placed on ice for 2 min prior to addition of ice cold EGFP-R8. The cells were 
then maintained under these conditions for 1 hr prior to analysis by confocal microscopy. 
 
2.6 Confocal microscopy  
Analysis was performed on a Leica SP5 confocal laser scanning microscope, equipped with 
laser lines: 405 Blue Diode (Excitation wavelength 405 nm for Hoechst 33342) Argon 
(Excitation wavelength 488 nm for Alexa 488 or EGFP), Helium Neon Laser 1 (Excitation 
wavelength 543 nm for Tetramethyl-Rhodamine Phalloidin (Rh-P)) and Laser 2 (Excitation 
wavelength 633 nm for Alexa 647 conjugates). All images presented in this study were 
obtained using a HCX PL APO 63× 1.4 NA oil immersion objective with Leica Type F 
immersion oil. Parameters “Gain” and “Off-set” of the individual photomultiplier tubes were 
adjusted between experiments in order to obtain optimal image acquisition avoiding saturation. 
For multi-channel image acquisition, the channels were scanned in a sequential recording mode 
to avoid spectral cross-talk caused by overlapping excitation and/or emission spectra of 
fluorophores. Acquisition mode “XYZ” and image resolutions (pixels/image) of 512×512 or 
1024×1024 were selected and pinhole size was set to 1 Airy Unit. Depending on acquisition 
requirements the scan speed was set as either 400 or 700 Hz and for single section images, the 
same optical section was scanned 3x to generate a line average image. Captured images were 
then analysed using ImageJ. In some cases (live cell imaging) the same cells were also imaged 
using Differential Imaging Contrast microscopy (DIC). 
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2.7 Actin cytoskeleton visualisation 
A recently described method was utilised giving information on actin architecture at different 
regions of the cells termed basal and cell body and apex (CBA).	For actin staining, HeLa (0.5 
× 10
6 
cells/well) or A431 (1.0 × 10
6 
cells/well) cells in 2.5 mL D-MEM containing 10 % FBS 
were seeded on round borosilicate No.1.5 cover slips in 6 –well plates and allowed to adhere 
for 24 hr at 37°C/5% CO2, to reach a confluence of ~80 %. The cells were then treated with 
actin disrupters as described above, washed 3x with PBS and fixed for 15 min at room 
temperature with 3 % PFA in PBS. Cells were then washed 3x with PBS and permeabilised 
with 0.2 % Triton X-100 in PBS at room temperature for 5 min, washed 3x with PBS and 
stained for cell nuclei with 1.0 µg/ml Hoechst 33342 in PBS and for polymerised actin with 
1.0 µg/ml Rh-P in PBS for 15 min at room temperature. The cells were finally washed 3x with 
PBS and once with distilled water,  coverslips were mounted in DAKO mounting medium on 
glass microscope slides and imaged by confocal microscopy 	19. 
2.8 Flow Cytometry 
A431 cells were seeded onto 12-well plates and cultured for 24 hr to be ~80% confluent on the 
day of experiment. Cells were washed twice with PBS and then incubated with diluent control 
(DMSO/dH2O) or actin inhibitors as previously described. They were then loaded with serum-
free DMEM containing either 2 µM EGFP-R8, 5 µg/ml TF-647 or 0.1 mg/ml Dex-647 in the 
presence or absence of actin inhibitors for times stipulated in the figure legends. The plates 
were then placed on ice to prevent further uptake and washed 3x with either ice-cold PBS or 
0.5 mg/ml heparin in PBS. To remove the plasma membrane bound TF, cells were washed 3x 
with ice-cold PBS followed by an incubation for 1 min in ice-cold acid wash (0.2 M acetic 
acid, 0.2 M NaCl, pH 2.0) 
33
.  All cells were then washed twice with PBS at room temperature 
before trypsinisation at 37°C for 5 min before placing the detached cells in centrifuge tubes 
and centrifuging at 4˚C for 3 min at 800 x g. The obtained cell suspension was washed 3x with 
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ice-cold PBS and finally resuspended in 300 µl ice-cold PBS for measurement of cell-
associated fluorescence (cell gate 50,000 cells) by flow cytometry on a BD FACSVerse 
utilising a 488 laser and 527/32 filter for EGFP analysis and a 633 nm laser and 660/10 filter 
for Alexa 647. Cells were gated using FSC-A/SSC-A to isolate single cell populations and 
analysed using FlowJo. 
2.9 Statistics 
Flow cytometry measurements represent the mean fluorescence from three independent 
experiments performed in duplicate, where each individual data point was the geometric mean. 
A two-tailed unpaired Students t-test was used to test for differences within experiments. 
Significant differences were classed as having a P value of < 0.05. 
2.10 Data Availability 
The datasets generated during the current study are available from the corresponding author on 
reasonable request. 
 
3 Results  
3.1 Cyt D effects on actin and endocytosis in HeLa and A431 cells  
Cyt D binds to the fast-growing ends of actin nuclei and filaments, preventing addition of 
monomeric actin to these sites. In our previous studies using flow cytometry we showed that 
Cyt D inhibited the uptake of Alexa488-CPPs R8 and Tat in two different cell models, HeLa 
and A431	
33
. But interestingly, the effect of actin disruption with this agent on the uptake of 
dextran was highly dependent on the choice of cell line as there was no effect in HeLa cells 
and an increased uptake in A431 cells. Here we further explored these contradictory effects by 
also performing uptake studies with recombinant EGFP-R8 following purification from E. Coli 
as described in Supplementary methods and Supplementary Fig. 1.  
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At 2 µM extracellular concentration, both R8 conjugates, in the two cell lines, labelled 
vesicular structures scattered throughout the cytoplasm as expected (Supplementary Fig. 2 and 
3). No cell associated fluorescence was observed for EGFP alone. We then performed the same 
experiments in cells incubated with Cyt D, focusing on effects on endocytosis and also cell 
morphology. 10 µM of the inhibitor was used as this concentration has previously been shown 
by different groups to inhibit the uptake of cationic CPPs such as HIV-Tat and R8 linked to 
different cargoes	
33-35
.  DIC microscopy highlighted the dramatic morphological effects on both 
cell lines incubated with this agent (Fig. 1 and Supplementary Fig. 4). Cyt D inhibited the 
internalisation of R8-Alexa 488 in HeLa cells (Fig. 1A), confirming our published data using 
flow cytometry	
33
. There was no clear evidence of Cyt D mediated inhibition of EGFP-R8 but 
the drug caused a scattering of the fluorescent structures compared to untreated cells that 
usually displayed strong juxtanuclear labelling (Fig. 1B). In contrast to HeLa cells there was 
less of a noticeable reduction in uptake of R8-Alexa488 in A431 cells but a clear change in 
subcellular distribution from evenly scattered throughout the cytoplasm in control cells to a 
largely clustered phenotype in treated cells (Fig. 1C). In contrast to the results obtained with 
R8-Alexa 488, Cyt D dramatically enhanced the internalisation of EGFP-R8 into small and 
large cytoplasmic structures (Fig. 1D). This data was confirmed in A431 cells using flow 
cytometry showing a highly significant 4.5 fold increase in intracellular fluorescence (Fig. 2), 
P = 0.0036. 
In these two cell lines, we also investigated the effects of Cyt D on the uptake of dextran, that 
enters cells via fluid phase uptake, and transferrin that enters via clathrin mediated endocytosis. 
In agreement with our previous flow cytometry and microscopy studies with 40KDa FITC and 
Alexa488 dextran 
33
, uptake of dextran-Alexa647 was dramatically increased in A431 cells 
(Supplementary Fig. 5 A, C). 
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Cell associated transferrin fluorescence was not markedly different between control and Cyt D 
treated HeLa cells (Supplementary Fig. 5 B) confirming previous reports performed at the same 
concentration in this cell line 
36
. Transferrin fluorescence in Cyt D treated HeLa cells was, 
however, more prominent on the plasma membrane compared to a strong perinuclear 
enrichment of fluorescence in control cells. Flow cytometry utilising acid washing of surface 
label confirmed that there was no difference in fluorescence uptake of transferrin in A431 cells 
treated with this drug (Supplementary Fig. 6), confirming previous studies in this cell line 
27
. 
We focused our further investigations on the A431 cell line and the EGFP-R8 peptide as this 
was the combination in which Cyt D had elicited the unusual uptake effects. 
 
Figure 1. Cytochalasin D effects on the cellular uptake of R8 conjugates in HeLa or A431 cells. HeLa (A,B) 
or A431 (C,D) were preincubated with 10 µM Cyt D or diluent control for 15 min prior to incubation with 2 µM 
R8 conjugates (R8-Alexa 488, A and C, or EGFP-R8, B and D) for 1 hr in the presence or absence of 10 µM Cyt 
D before washing in heparin and analysis by confocal microscopy. Shown are single projection images of 
fluorescence only (R8-Alexa 488/EGFP-R8), DIC and merges of fluorescence and DIC of the same cells. Scale 
bars 10 µm.  
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Figure 2. Cytochalasin D treatment increases the cellular uptake of EGFP-R8 in A431 cells. Cells were 
preincubated with 10 µM Cyt D or diluent control for 15 min prior to incubation with 2 µM EGFP-R8 in the 
absence or presence of 10 µM Cyt D for 1 hr. Cells were then washed, trypsinised and analysed by flow cytometry. 
Data represent the geometric means ± S.D. from three independent experiments.  
 
To identify whether the enhanced cellular uptake of EGFP-R8 in A431 cells by Cyt D treatment 
was an energy dependant process, the same experiments were performed with cells pre-
incubated at 37˚C with the drug, then placed on ice and maintained at 4 ˚C throughout the 
subsequent incubation with EGFP-R8. There was very little evidence above background 
fluorescence that EGFP-R8 entered cells at 4˚C in the presence or absence of Cyt D 
(Supplementary Fig. 7) confirming that the enhanced EGFP-R8 internalisation induced by the 
inhibitor was energy dependent.  
To try and identify the subcellular compartments occupied by EGFP-R8 we performed 
pulse/chase experiments with Dex-647: a 2 hr pulse labelled endolysosomal organelles was 
followed by a 4 hr chase to specifically label late endosomes and lysosomes 
37
.  EGFP-R8 was 
then incubated with the cells for 1 hr in the presence or absence of Cyt D. Control cells 
(Supplementary Fig. 8A, top row, indicated by arrows) show colocalisation of the two 
fluorophores demonstrating trafficking of some EGFP-R8 to dextran labelled late endosomes 
and lysosomes. However, EGFP only structures were also clearly visible suggesting that this 
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fraction had not yet entered these structures or were trafficking to a different location.  To 
verify that the EGFP fluorescence was being emitted from inside the cells we captured images 
of the Cyt D treated cells through the Z axis starting 1.44µm from the glass surface to a height 
of 14.5µm. This allowed us to visualise the dextran and EGFP-R8 structures at different focal 
planes and the data confirmed that the EGFP fluorescence was of intracellular origin 
(Supplementary Fig. 8B). 
 
3.2 Effects of other actin reagents on actin and cellular uptake of EGFP-R8 
Lat B, binds to and complexes with actin monomers at a 1:1 molar ratio and prevents 
polymerisation 
38
. We initially investigated the concentration dependent effects of this drug on 
the actin cytoskeleton. At the lowest concentration (0.1 µM) the drug caused the formation of 
small actin aggregates at both the basal and cell body and apex (CBA) sections of the cells 
(Fig. 3). At 0.5 µM, these aggregates were extremely prominent especially at the basal section. 
At 1 µM the drug caused major disruption of the actin organisation manifest as amorphous 
structures scattered throughout the cytoplasm. The effects of this drug on cell morphology is 
further highlighted in Supplementary Fig. 4. 
We subsequently performed CPP uptake experiments in A431 cells pre-incubated with 0.5 µM 
Lat B prior to addition of EGFP-R8. The effect of Lat B (Fig. 4) was comparable to that of Cyt 
D (Fig. 2): the inhibitor treated cells showing much higher fluorescence compared to controls 
(Fig. 4). Flow cytometry analysis confirmed these findings and the 6.23 fold increase in uptake 
was highly statistically significant (P=0.0045).  
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Figure 3. Effects of Lat B on the actin architecture in A431 cells. Cells on coverslips were treated either with 
diluent control (0.1% DMSO) or 0.1-1.0 µM Lat B for 30 min before fixing and staining with Rh-P and Hoechst. 
Single sections (A) show the overall distribution of the actin relative to the nucleus. (B) Actin arrangement from 
the basal, CBA regions and composite (Merge) of basal and CBA. Scale bars 10 µm.  
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Figure 4. Effects of Lat B on the cellular uptake of EGFP-R8 in A431 cells. Cells were preincubated with 
either with diluent control or 0.5 µM Lat B for 30 min prior to incubation with 2 µM EGFP-R8 for 1 hr in the 
absence (control) or presence of 0.5 µM Lat B and washed in heparin. (A) Cell associated fluorescence was 
analysed using confocal microscopy and shown are single projection images of fluorescence only (top rows) and 
merges of fluorescence and DIC of the same cells. Scale bars 10 µm. (B) Cells treated as in A were washed, 
trypsinised and analysed by flow cytometry. Data represent the mean of geometric means ± S.D. from three 
independent experiments. 
 
An alternative actin inhibitor, Jasplakinolide (JAS) binds directly to filamentous actin and 
unlike Cyt D and Lat B induces stabilisation of the existing actin filaments thus inhibiting actin 
disassembly 
39-42
. Compared with control cells, no visible changes in actin organisation were 
observed in both basal and CBA sections of cells until the concentration of JAS reached 0.2 
µM (data not shown and Fig. 5). At this concentration, actin staining was more prominent on 
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the cell periphery at both basal and CBA regions. At 2µM JAS the actin staining appeared in 
large clumps, previously identified as aggresomes 
43
, or was absent, and was completely lost 
from all cells treated at 4µM (Fig. 5A).  This loss of fluorescence may be due to the fact that 
this drug has been shown to be a competitive inhibitor of phalloidin-actin binding 
39
. 
Supplementary Fig. 4 shows the significant morphological effects of this drug on the cells. 
Confocal microscopy dramatic increase in EGFP-R8 uptake in JAS treated cells (Fig. 6A) and 
the drug caused a pronounced clustering of fluorescence in the cytoplasm. Equivalent 
experiments analysed by flow cytometry (Fig. 6B) indicated that JAS induced a four-fold 
increase in fluorescence that was statistically significant (P=0.0025). The diluent control 
experiments with JAS required adding DMSO to the cells at a final concentration of 0.4% v/v; 
the highest used in this study. This concentration did not affect uptake of EGFP-R8 or R8-
Alexa488 (Supplementary Fig. 9). 
 
Figure 5. Effects of JAS on the actin architecture in A431 cells. Cells on coverslips were treated either with 
diluent control (0.1% DMSO) or 0.2, 2.0 or 4.0 µM JAS for 45 min before fixing and staining with Rh-P and 
Hoechst. (A) Single sections show the overall distribution of the actin relative to the nucleus. (B) Actin 
arrangement from the basal, CBA regions and composite (Merge) of basal and CBA. Scale bars 10 µm. 
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Figure 6. Effects of JAS on the cellular uptake of EGFP-R8 in A431 cells. Cells were preincubated with diluent 
control or 2-4 µM JAS for 45 min prior to incubation with 2 µM EGFP-R8 for 1 hr in the absence (control) or 
presence of 2-4 µM JAS and washed thoroughly using heparin. (A) Cell associated fluorescence was analysed 
using confocal microscopy and shown are single projection images of fluorescence only (top row) and merges of 
fluorescence and DIC of the same cells. Scale bars 10 µm. (B) Cells treated as in A with 4µM JAS were then 
washed, collected and analysed by flow cytometry. Data represent the mean of geometric means ± S.D. from three 
independent experiments. 
 
Actin dynamics and regulation are achieved through the concerted action of actin regulatory 
proteins whose activities are finely modulated by protein kinases. These include Rho-
associated coiled-coil forming serine/threonine kinases ROCK I and II that have been identified 
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as important downstream effectors of RhoA through their interaction with its GTP-bound form 
44,45
. A number of chemical inhibitors of the Rho-ROCK signalling cascade have been 
developed, including compound Y27632 [(+) -(R) - trans - 4 - (1-aminoethyl) - N - (4-pyridyl) 
cyclohexanecarboxamide dihydrochloride]. This has been shown to inhibit the kinase activity 
of a number of ROCKs by binding to their catalytic sites 
46,47
. Initially, 1 and 10 µM 
concentrations of Y27632 were investigated on actin localisation, based on published 
observations showing actin deformities at these concentrations 
46,48
. Supplementary Fig. 10 
demonstrates that no visible changes in the organisation of the actin cytoskeleton were detected 
up to 10 µM drug. Higher concentrations caused extensive actin deformities including the 
formation of a large number of actin needles, the majority of which ran perpendicular to the 
plasma membrane (Fig. 7).  
In CPP uptake experiments, Y27632 treated cells displayed scattered EGFP-R8 fluorescence 
in small vesicles in contrast to the vesicle aggregates seen in cells incubated with the other 
actin disrupting agents (Fig. 1, 4 and 8A) while DIC microscopy did not show the gross 
morphological effects caused by the other actin inhibitors. Flow cytometry analysis indicated 
that cell uptake of EGFP-R8 uptake was significantly inhibited by Y27632 but only by ~20% 
(Fig. 8B P=0.02). To exclude the possibility that any of the actin inhibitors was affecting 
plasma membrane permeability, we incubated A431 cells with the inhibitors at the 
concentrations and incubations used above in the presence of live cell impermeable dye - 
DRAQ7. Using Tritin X-100 as positive control, none of the inhibitors showed any evidence 
of inducing plasma membrane permeabilisation (Supplementary Fig. 4). 
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Figure 7. Effects of Y27632 on the actin architecture of A431 cells. Cells on coverslips were treated either with 
diluent control (D-MEM) or 50, 100 µM of Y27632 for 4 hr before fixing and staining with Rh-P and Hoechst. 
(A) Single sections show the overall distribution of the actin relative to the nucleus. (B) Actin arrangement from 
the basal, CBA regions and composite (Merge) of basal and CBA. Scale bars 10 µm. 
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Figure 8. Effects of Y27632 on the cellular uptake of EGFP-R8 in A431 cells. Cells were preincubated with 
diluent control or 100 µM Y27632 for 4 hr prior to incubation with 2 µM EGFP-R8 for 1 hr in the absence 
(control) or presence of 100 µM Y27632 and washed with heparin. (A) Cell associated fluorescence was analysed 
using confocal microscopy and shown are single projection images of fluorescence only and merge of 
fluorescence and DIC of the same cells. Scale bars 10 µm. (B) Cells were washed, trypsinised and analysed by 
flow cytometry. Data represent the mean of geometric means ± S.D. from three independent experiments. 
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4. Discussion  
Since the discovery of CPPs, considerable efforts have been made to elucidate their 
internalisation mechanisms. Focusing mainly on arginine rich variants, macropinocytosis has 
been proposed to be a major contributing pathway for delivery of low molecular weight 
fluorophores or larger cargo by these peptides	
20,24,49
. This is based on studies utilising chemical 
macropinocytosis inhibitors including, and almost exclusively Cyt D for actin inhibition. It 
should however be noted that the involvement of actin activity has been shown for other 
endocytic pathways such as clathrin-mediated endocytosis (CME) 
27,50
.  As shown here and in 
several other studies, Cyt D at concentrations >5µM, completely destroys actin organisation 
and, unsurprisingly, cell morphology is also compromised.  A number of other natural 
compounds and synthetic products have been identified or developed to target the actin 
cytoskeleton directly or indirectly and to disrupt its arrangement/ function. These include Lat 
B, JAS and Y27632 and these inhibitors have not been used to support Cyt D data for drug 
delivery endocytosis studies, including CPPs. To our knowledge this is the first study that has 
analysed CPP uptake with actin inhibitors employing different mechanisms of action.  
By employing high content analysis of the actin architecture using confocal microscopy and 
then flow cytometry we were able to correlate actin disorganisation with cellular uptake of 
EGFP-R8 as a model protein-CPP conjugate.  EGFP has been shown to be delivered into cells 
by R8 and R9 
35,51
 but correlative information regarding the uptake mechanism of the proteins 
relative to that of the peptides attached to fluorophores is lacking. EGFP-Tat uptake has been 
proposed to be mediated via macropinocytosis and caveolae	
24,52
.  Both octaarginine and Tat 
peptides together with longer and shorter number of arginine residues (R7, R9) have also been 
shown to deliver proteins into cells to mediate biological effects 
53-55
. 
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In this study, HeLa cells reacted in a somewhat predictable manner in response to actin 
breakdown with Cyt D showing a reduction in uptake of R8-Alexa488 and dextran. In this cell 
line EGFP-R8 uptake was also inhibited by Cyt D treatment suggesting a similar mechanism 
of uptake. We have previously shown that cortical actin in A431 cells is particularly prominent 
and suggested that this may have a role in the uptake of dextran that, under normal conditions, 
enters cells via constitutive pinocytosis; also termed fluid phase endocytosis. This can be 
differentiated from stimulus induced macropinocytosis 
56,57
. This potential for the involvement 
of cortical actin was identified by discovering a rather unexpected and highly significant 
increase in the uptake of 10 and 40KDa dextran in Cyt D treated A431 cells that was not 
observed with Alexa conjugates of transferrin, Tat and R8	
33
. 
In this study in we show that dextran and also EGFP-R8 uptake is significantly increased in 
A431 treated with Cyt D and contrasts to that observed for R8-Alexa488 (inhibition) and 
transferrin (no change).  This strongly suggests that the process by which these two R8 
conjugates interact with and/or enter cells is different. It should be noted that the structure of 
both conjugates differ in their cargo-CPP orientation and also the linkers utilised between them. 
We consider that it is highly unlikely that these factors mediate the differences in endocytic 
profiles of these conjugates. Due to the similarities we see in entry for dextran and EGFP-R8, 
we hypothesise that the differences are driven by the cargo and not the orientation of the CPP. 
But this warrants further study, noting that EGFP alone does not enter these cells at the 
concentrations used here, demonstrating a clear role for R8 that may be interacting differently 
with cells when attached to a fluorophore or protein. In none of the experiments performed did 
we observe clearly defined cytosolic EGFP fluorescence in Cyt D treated cells demonstrating 
that the effects of this drug maintained the localisation of the protein within a membrane bound 
compartment.  
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We have previously shown that R8 and Tat peptides as Alexa conjugates traffic rapidly by 
endocytosis to reach lysosomes 
30
 and by performing pulse chase experiments we now show 
that the same is true for EGFP-R8, demonstrating that it is trafficked to the same degradative 
compartments. From these combined studies we also highlight that traffic to lysosomes of R8 
attached to different cargo is also entirely dependent on functional actin.  
Our findings prompted us to further study EGFP-R8 uptake in cells treated with inhibitors of 
actin that operate via different mechanisms and affect actin dynamics in different ways. Like 
Cyt D, at effective actin disrupting concentrations, JAS and Lat B also affected cell 
morphology and increased EGFP-R8 uptake that was again highly enriched in large structures 
in particular regions of the cells. Previous studies in non-polarised epithelial MDCK cells 
demonstrated that JAS treated cells had much higher levels of internalised and retained dextran 
compared with control cells 
57
.  In polarised cells, however, this effect was limited to dextran 
entering via the basolateral surface and the retained dextran was observed in large structures 
as we observe for EGFP-R8.  It remains to be determined whether EGFP-R8 would also behave 
in a similar manner when introduced to different surfaces of polarised cells and whether this is 
influenced by any differences in cortical tension between these surfaces. The nature of these 
large structures is unknown but may be formed by tubulation of the plasma membrane that has 
been shown to be caused by Cyt D 
58
.  The	plasma	membrane	tension	of	mammalian	cells	is	
coordinated	 and	 maintained	 through	 the	 actin	 network,	 and	 this	 profoundly	 influences	
endocytosis 
59,60
. The reduced cortical tension resulting from actin disruption in MDCK 
basolateral surfaces
57
 and here in A431, cells may favour the formation of invaginations and 
tubulation to allow entry of macromolecules. This strongly supports Studies showing an 
increased uptake of 70KDa dextran and the folic acid receptor in Cyt D treated cells 
61,62
. Both 
folic acid and dextran have been extensively utilised as, respectively, targeting and passive 
vectors for drug delivery	
25,63
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Through interaction with the Rho GTPase, ROCKs play a central role in actin network 
assembly and membrane association	
64
. In A431 cells the effects of Y27632 on the actin 
cytoskeleton was more subtle than that observed with the agents that directly targeted actin. 
No change in cell morphology was observed in treated cells but actin distribution was very 
different at high 100 µM concentrations. Effects of this agent in human trabecular meshwork 
eye cell actin has been shown to be extremely prominent at much lower concentrations, 
showing a loss of filamentous actin	
65
.	In contrast to results observed with direct actin inhibitors, 
we observed a slight but significant decrease in the uptake of EGFP-R8 in cells treated with 
Y27632. To our knowledge no CPP studies have been performed with this drug though it has 
previously been shown to affect the internalisation of plasma membrane receptors and also to 
inhibit (~50%) the uptake of 70 KDa dextran in macrophages 
66-68
. This again supports our 
suggestion that dextran and EGFP-R8 uptake is responsive to the same inhibition in A431 cells 
but that they may not necessarily enter via the same mechanism. This supports recent 
observations showing that cell uptake profiles of HIV-TAT peptide and dextran can be 
separated
69
. 
5. Conclusions  
Interpretation of endocytosis data in in vitro models obtained using actin modifying agents is 
difficult as the network that this protein nucleates is a regulator of so many processes and global 
cell morphology is often affected by its perturbation.  Here we highlight that disruption of actin 
in some cell types promotes cell uptake of specific molecules whilst having no effects, or even 
inhibitory effects on others. From careful scrutiny of the literature there is precedent for this in 
other cell types and distinct plasma membrane regions in polarised cells. The possibility exists 
that these cells have a specific but common cortical organisation of actin that could be exploited 
to drive internalisation of drug delivery vectors carrying macromolecular therapeutics. 
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Supplementary Information 
Supplementary method 1: Expression and purification of recombinant proteins 
BL21 (DE3) E.coli (Novagen, Feltham, UK) were transformed with a pEV3b plasmids  containing  
His6-EGFP or His6-EGFP-R8 transformed cultures were induced using 0.5 mM IPTG (Sigma-Aldrich, 
Poole, UK) for 3 hr. Proteins were purified under native conditions by affinity chromatography on Ni-
NTA (nickel-nitrilotriacetic acid) resin column (Qiagen, Manchester, UK). The purity of the expressed 
protein was analysed using SDS-PAGE (Supplementary Fig 1A,B) and both proteins were then dialysed 
overnight against phenol red-free D-MEM in 20 kDa molecular weight cut off Slide-A-Lyzer dialysis 
cassettes (Life Technologies, Paisley, UK), MALDI-TOF analysis showed the purified EGFP-R8 to 
have a mass of 29125.00 (Supplementary Fig. 1C). Aliquots (50µl) of 50µM concentration were stored 
at -80˚C until needed.  
 
Supplementary method 2: Cell permeability assay of A431 cells in presence of inhibitors 
A431 cells were seeded on MatTek dishes as described in section 2.4 of main manuscript.  On the day 
of experiment cells were preincubated with the inhibitors as described in section 2.5, with the addition 
of a DMSO control (0.4% DMSO in serum-free D-MEM (SFM), 45 min pre-incubation), negative 
control (SFM, 45 min pre-incubation) and a positive control (0.1% Triton X100 in SFM, no 
preincubation). Cells were then re-incubated with fresh inhibitor, or control solution for 1 hr in the 
presence of 3 µM DRAQ7 (abcam, Cambridge, UK) to mimic the CPP incubation period. Finally, cells 
were washed three times in SFM before imaging by confocal microscopy (section 2.6 of main 
manuscript). 
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Supplementary Figure 1  
 
 
Supplementary Figure 1. Purification of EGFP conjugates. Crude cell lysate (40 µg; lane 1) 
containing (A) His6-EGFP-R8 or (B) His6-EGFP obtained from a 5 L E. coli preparation was applied 
to an equilibrated Ni-NTA resin column. Samples were collected from the initial Flow-through and then 
following four washes of buffer (20 mM Tris-HCl pH 7.5, 400 mM NaCl) containing increasing 
concentrations of 20-50 mM imidazole. The remaining material was eluted with buffer containing 250 
mM imidazole and protease inhibitor cocktail. Sample (20 µl) from each wash (lane 4-7) and 2 µg of 
the eluted His6-EGFP-R8 (A, lane 8) or His6-EGFP (B, lane 8) were run on a 12% SDS-PAGE gel and 
visualised by Coomassie blue staining. The eluted samples (lane 8) were then dialysed against DMEM. 
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(C) MS Spectra of EGFP-R8 analysed on a Waters Synapt G2-Si mass spectrometer. Left, deconvoluted 
spectrum (theoretical: 29125.02, observed: 29125.00). Right, ESI-MS before deconvolution. 
Supplementary Figure 2 
 
Supplementary Figure 2. Endocytosis of R8-Alexa 488 and EGFP-R8 in HeLa cells. Cells were 
washed and incubated with 2 µM R8-Alexa 488, EGFP-R8 or EGFP in serum free D-MEM for 1 hr, 
and analysed by confocal microscopy. Images shown are single sections, DIC profiles and merged 
overlays. Scale bars 10 µm.  
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Supplementary Figure 3 
 
 
Supplementary Figure 3. Endocytosis of R8-Alexa 488 and EGFP-R8 in A431 cells. Cells were 
washed and incubated with 2 µM R8-Alexa 488, EGFP-R8 or EGFP in serum free D-MEM for 1 hr, 
and analysed by confocal microscopy. Images shown are single sections, DIC profiles and merged 
overlays. Scale bars 10 µm. 
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Supplementary Figure 4 
 
 
Supplementary Figure 4. Membrane permeability analysis of inhibitors utilised in this study. 
A431 cells were pre-incubated with the inhibitor for a specified time before being incubated for 1hr in 
the presence of cell permeation marker DRAQ7 (3 µM, red). Brackets also indicate final concentration 
of DMSO utilised with inhibitor (Y27632 contained no DMSO). Images represent single sections taken 
by confocal microscopy using 40X objective, scale bars = 20 µm 
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Supplementary Figure 5 
 
Supplementary Figure 5. Cyt D effects on the cellular uptake of transferrin or dextran in HeLa 
or A431 cells. HeLa (A, B) and A431 (C, D) cells were pre-treated with 10 µM Cyt D or diluent control 
for 15 min prior to incubation with 5 µg/ml Transferrin-Alexa647 (B, D TF-647) for 30mins or 0.1 
mg/ml 10kD dextran-Alexa 647 (A, C Dex-647) for 1 hr in the absence or presence of 10 µM Cyt D 
before washing and analysis by confocal microscopy. Shown are single projection images of 
fluorescence only (TF-647/Dex-647), DIC and merges of fluorescence and DIC of the same cells. Scale 
bars 10 µm.  
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Supplementary Figure 6 
 
 
Supplementary Figure 6. Effects of Cyt D treatment on the cellular uptake of Transferrin-
Alexa647 (TF-647) by A431 cells. Cells were pre-treated with 10 µM Cyt D or diluent control for 
15 min prior to an incubation with 5 µg/ml TF-647 in the absence or presence of 10 µM Cyt D for 
30 min. Cells were then washed, collected and analysed by flow cytometry. Data represent the mean of 
geometric means ± S.D. from three separate experiments.  
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Supplementary Figure 7 
 
Supplementary Figure 7 Cellular uptake of EGFP-R8 in control or Cyt D-treated A431 cells at 
4°C or 37°C. Cells were pre-treated with 10 µM Cyt D or diluent control for 15 min prior to incubation 
with 2 µM EGFP-R8 in the absence (control) or presence of 10 µM Cyt D for 1 hr at 4°C or 37°C, 
washed with heparin and analysed using confocal microscopy and shown are single projection images 
of fluorescence only (top rows) and merges of fluorescence and DIC of the same cells. Scale bars 10 
µm.  
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Supplementary Figure 8 
 
Supplementary Figure 8. Co-localisation of EGFP-R8 and dextran10-Alexa647 (Dex-647) in A431 
cells treated with Cyt D. Cells were incubated with 0.1 mg/ml Dex-647 for 2 hr followed by 4 hr chase 
in fresh growth medium. Cells were then pre-treated with 10 µM Cyt D or diluent control for 15 min 
prior to incubation with EGFP-R8 (2 µM) for 1 hr in the absence or presence of 10 µM Cyt D. Cell 
associated fluorescence was analysed using confocal microscopy. (A) Single section images of EGFP-
R8 (green) or Dex-647 (red) fluorescence and merges of fluorescence with or without DIC of the same 
cells. Arrows depict colocalisation, solid arrows depict non-colocalised EGFP-R8 and hollow arrows 
depict non-colocalised Dex-647. (B) Cells incubated in the presence of 10 µM Cyt D as above, single 
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section images of the Z-axis of the cells from the glass surface to a height of 14.5µm single section 
images of fluorescence (EGFP-R8, green and Dex-647, red). Scale bars 10 µm. 
Supplementary Figure 9 
 
Supplementary Figure 9. Uptake of EGFP-R8 and R8-Alexa488 in the presence and absence of 
DMSO in A431 cells. (A) Cells were preincubated with 0 or 0.4% DMSO in SFM for 45 mins before 
re-incubation in 0 or 0.4% DMSO in the presence of either 2 µM EGFP-R8 or 2 µM R8-Alexa488 for 
1 hr and analysed by flow cytometry as described in materials and methods of the main manuscript. 
Data represents the mean of the geomeans ± S.D from three independent experiments. (B) Cells 
incubated with or without DMSO as above were fixed and stained for actin using rhodamine-phalloidin 
and nucleus labelled with Hoechst33342. Scale bars = 10 µm 
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Supplementary Figure 10 
 
Supplementary Figure 10. Effects of ROCK inhibitor Y27632 (low concentrations) on the actin 
architecture in A431 cells. Cells on coverslips were treated either with diluent control or 1 or 10 µM 
Y27632 for 4 hr before fixing and staining with Rh-P and Hoechst. (A) Single sections show the overall 
distribution of the actin relative to the nucleus. (B) Actin arrangement from the basal, CBA regions and 
composite (Merge) of basal and CBA. Scale bars 10 µm.  
 
	
